The American Society of Clinical Oncology‘s effort to use big data and EHRs to earlier detect cancer just got a $1 million boost from pharma giant Bayer Healthcare.
The Society, better known as ASCO, recently launched the effort dubbed CancerLinQ with Germany-based SAP, creating what’s described as an IT platform “designed to unlock vast quantities of information about the experiences of people living with cancer.”
By potentially harnessing big data, ASCO and SAP hope to study 97 percent of adult cancer patients who aren’t currently participating in clinical trials.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
“Instead of learning from only the three percent of cancer patients who participate in clinical trials, CancerLinQ will allow oncologists to learn from almost every patient,” said ASCO President Peter Paul Yu in a statement.
As part of the effort, eight oncology centers around the country will use CanderLinQ, which will analyze millions of health records.
SAP’s software includes predictive text analytics, spatial processing and data virtualization. The collaboration with ASCO is one of several health-related efforts for SAP, having previously applied its software with the National Center for Tumor Diseases in Germany, to assist cancer research and improve clinical trial matching.
“
